[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Alves AP, Pessoa Cdo O, Costa-Lotufo L, Moraes Filho MO: Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma. Acta Cir Bras; 2007 Nov-Dec;22(6):457-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma.
  • PURPOSE: To investigate the effects of bisphosphosnate alendronate (ALD) and metotrexate (MTX) on an experimental model of Walker 256 carcinosarcoma developed in the oral cavity of rats.
  • METHODS Walker 256 carcinosarcoma cell suspension (0,1 mL) containing 10(6) cell/mL was implanted in the alveoli of the first and second molars.
  • CONCLUSION: The bisphosphonate alendronate exherted an osteoprotective effect and induced bone neoformation on the Walker 256 carcinosarcoma inoculated in rat mandibles.
  • The combination of metotrexate with bisphosphonate alendronate is more successful than treatment with the agents alone in controlling the growth of neoplastic cells and in stimulating reactive new bone.
  • Therefore, this may be an alternative treatment to malignant lesions of maxillaries with osteolysis.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. Alendronic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235934.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; X1J18R4W8P / Alendronate; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Paterson AH: The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer; 2000 Jun 15;88(12 Suppl):3038-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.
  • Within the family of BPs there are more similarities in pharmacologic effects than differences, although side effect profiles, rates of oral absorption, and potency do differ.
  • Oral clodronate and intravenous pamidronate reduce skeletal complications in patients with bone metastases from breast carcinoma (as well as in myeloma).
  • Uncontrolled trials of prostate carcinoma also suggest clinical benefit.
  • METHODS: Animal studies show that BPs can reduce the rate of development of bone metastases (for example, in Walker 256 carcinoma), but there is little evidence of an effect at nonosseous sites.
  • RESULTS: In patients with recurrent breast carcinoma but no overt bone metastases, oral clodronate reduced the number of diagnosed bone metastases; but the number of patients who had relapses in bone, though smaller, was not significantly different from the number among patients who took placebo.
  • Patients treated for operable breast carcinoma have four or five times the normal rate of vertebral fracture, and BPs do reduce the rate of bone loss.
  • ), showed a reduction in osseous and nonosseous recurrences and an increase in disease free and overall survival with 2 years of clodronate.
  • A second open-label trial (Saarto et al.) of similar size involving lymph node positive breast carcinoma patients showed no effect on the rate of bone metastasis relapse and a deleterious effect on relapse rates of nonosseous metastases with 3 years of clodronate.
  • A third placebo-controlled trial involving 1079 patients reported, in an interim analysis, a reduction in osseous metastases during treatment with 2 years of clodronate, but no effect on nonosseous metastases or survival.
  • 1) scientifically, it is important to demonstrate that an agent that has its dominant effect on a normal tissue cell, the osteoclast, can influence the growth of neoplastic cells; and 2) from the perspective of patient care, it must be unequivocally shown that a reduction in the rate of osseous recurrence translates into an improvement in disease free survival or an improvement in quality of life through reduction of adverse skeletal events.
  • The National Surgical Adjuvant Breast Project has committed to conducting this study and including women with operable breast carcinoma.
  • [MeSH-major] Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Diphosphonates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Clinical Trials as Topic. Female. Humans. Spinal Fractures / etiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10898349.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 62
  •  go-up   go-down


3. Welchinskaya HV, Piecuszak B, Kovalenko EA, Sharykina NI, Getman KI, Podgorsky VS: Biological activity of bacterial lectins and their molecular complexes with heterocyclic bis-adducts. Mikrobiol Z; 2003 Sep-Oct;65(5):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was discovered that these substances apply to a few toxic preparations and have a expression antitumour action on the tumours: Walker carcinosarcoma 256, Pliss' lymphosarcoma and Sarcoma 45.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / therapeutic use. Heterocyclic Compounds / chemistry. Lectins / chemistry. Lectins / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Bacillus / chemistry. Benzimidazoles / chemistry. Carcinoma 256, Walker / drug therapy. Crown Ethers. Halothane / chemistry. Imidazoles / chemistry. Lethal Dose 50. Lymphoma, Non-Hodgkin / drug therapy. Mice. Rats. Sarcoma, Experimental / drug therapy. Uracil / chemistry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE .
  • Hazardous Substances Data Bank. BENZIMIDAZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14723158.001).
  • [ISSN] 1028-0987
  • [Journal-full-title] Mikrobiolohichnyĭ zhurnal (Kiev, Ukraine : 1993)
  • [ISO-abbreviation] Mikrobiol. Z.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Crown Ethers; 0 / Heterocyclic Compounds; 0 / Imidazoles; 0 / Lectins; 56HH86ZVCT / Uracil; 63J177NC5B / 18-crown-6; 7GBN705NH1 / imidazole; E24GX49LD8 / benzimidazole; UQT9G45D1P / Halothane
  •  go-up   go-down


Advertisement
4. Clichici S, Filip A, Daicoviciu D, Ion RM, Mocan T, Tatomir C, Rogojan L, Olteanu D, Muresan A: The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin. Acta Physiol Hung; 2010 Mar;97(1):41-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin.
  • Photodynamic therapy (PDT) is a promising therapy especially in skin cancer, using the systemic administration of a photosensitizer (PS), followed by the local irradiation of the tumor with visible light.
  • Our study evaluates the effects of PDT with TSPP upon the tumor levels of ROS and upon the metalloproteinases 2 (MMP2) activities on Wistar male rats bearing 256 Walker carcinosarcoma in correlation with the accumulation of PS in the tumor and with the intratumor histological alterations.
  • Our results emphasize that 24 hours after the PDT with TSPP, the ROS generation increases, as revealed by protein carbonyls and malondialdehyde levels and the antioxidant capacity (hydrogen donors, thiol groups) decreases in the tumor tissue.
  • [MeSH-major] Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism. Photochemotherapy. Porphyrins / therapeutic use. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Animals. Antioxidants / metabolism. Kinetics. Male. Matrix Metalloproteinase 2 / metabolism. Oxidative Stress / drug effects. Photosensitizing Agents / pharmacology. Photosensitizing Agents / therapeutic use. Rats. Rats, Wistar. Time Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233689.001).
  • [ISSN] 0231-424X
  • [Journal-full-title] Acta physiologica Hungarica
  • [ISO-abbreviation] Acta Physiol Hung
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / Reactive Oxygen Species; 35218-75-8 / tetraphenylporphine sulfonate; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


5. Sugahara S, Okuno S, Yano T, Hamana H, Inoue K: Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol Pharm Bull; 2001 May;24(5):535-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting.
  • Using the Walker 256 model for carcinosarcoma-bearing rats, we intravenously administered 5 polysaccharide carriers with various molecular weights (MWs) and electric charges and tested for their plasma and tissue distribution.
  • As for the anionic charge, CMDex (110-180 kDa) with a degree of substitution (DS) of the CM groups ranging from 0.2 to 0.6, showed maximum plasma AUC values.
  • Doxorubicin (DXR) was bound to these carriers via a peptide spacer, GlyGlyPheGly (GGFG), to give carrier-GGFG-DXR conjugates (DXR content: 4.2-7.0 (w/w)%), and the antitumor effects of these conjugates were tested with Walker 256 carcinosarcoma-bearing rats by monitoring the tumor weights after a single intravenous injection.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Carriers. Polysaccharides / pharmacokinetics
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Doxorubicin / administration & dosage. Female. Molecular Weight. Rats. Rats, Wistar. Tissue Distribution

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11379776.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Polysaccharides; 80168379AG / Doxorubicin
  •  go-up   go-down


6. Rotinberg P, Kelemen S, Gramescu M, Rotinberg H, Nuta V: Preclinical qualitative evaluation of the antitumoral pharmacodynamic action of some natural polyphenolic biopreparations. Rom J Physiol; 2000 Jan-Dec;37(1-4):91-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of in vivo tests of their effect on the development of Guerin T-8 lymphotropic epithelioma and Walker 256 carcinosarcoma were conducted.
  • All those results highlighted the antineoplastic pharmacotherapeutic effect of the polyphenolic biopreparations and also proved that effect to be replicable.
  • The qualitative evaluation of the pharmacodynamic action of those preparations was a condition for their further quantitative pharmacological evaluation in point of antitumoral therapeutic effectiveness in a preclinical stage.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413150.001).
  • [ISSN] 1223-4974
  • [Journal-full-title] Romanian journal of physiology : physiological sciences
  • [ISO-abbreviation] Rom J Physiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polymers; 0 / Polyphenols
  •  go-up   go-down


7. Tandon VK, Yadav DB, Chaturvedi AK, Shukla PK: Synthesis of (1,4)-naphthoquinono-[3,2-c]-1H-pyrazoles and their (1,4)-naphthohydroquinone derivatives as antifungal, antibacterial, and anticancer agents. Bioorg Med Chem Lett; 2005 Jul 1;15(13):3288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The structure-activity relationship of these compounds was studied and the results show that the compound 2b exhibited in vitro antifungal activity against Candida albicans and Cryptococcus neoformans, and also possessed antibacterial profile against Klebsiella pneumoniae and Escherichia coli whereas 1c showed anticancer activity against Walker 256 Carcinosarcoma in rats.
  • [MeSH-minor] Animals. Candida albicans / drug effects. Carcinoma 256, Walker / drug therapy. Cryptococcus neoformans / drug effects. Escherichia coli / drug effects. Klebsiella pneumoniae / drug effects. Microbial Sensitivity Tests. Naphthoquinones / pharmacology. Rats. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913995.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Naphthoquinones; 0 / Pyrazoles
  •  go-up   go-down


8. Luboldt W, Pinkert J, Matzky C, Wunderlich G, Kotzerke J: Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr Drug Deliv; 2009 Jul;6(3):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Success of selective drug therapies depends on the drug's depot time in the target to treat.
  • Depot time is currently being prolonged, using drug-eluting beads or microspheres for selective internal radiation therapy.
  • The purpose of this study was to establish a model for investigating the depot time of particles injected into tumors in relation to tumor vascularization and particle size.
  • MATERIALS AND METHODS: An animal model with two different vascularized tumors (Walker Carcinoma 256 (hypervascularized) and Yoshida Sarcoma (hypovascularized)) was used.
  • Tumor activity was measured with a gamma camera at 10 min, 1h, 3h, 6h, 14h and 48h p.i.
  • Measurements were adjusted for decay times and then compared.
  • CONCLUSIONS: Particle stay time, biodistribution, and stability can be easily monitored as shown in this animal model.
  • Prolonged retention is independent of vascularization and particle size and appears to be sufficient for therapy.
  • [MeSH-minor] Animals. Carcinoma 256, Walker / blood supply. Carcinoma 256, Walker / metabolism. Epinephrine / pharmacology. Female. Humans. Injections, Intralesional. Kidney / metabolism. Liver / metabolism. Lung / metabolism. Radioisotopes / chemistry. Rats. Rats, Wistar. Rhenium / chemistry. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / metabolism. Serum Albumin / chemistry. Spleen / metabolism. Sulfur / chemistry. Tissue Distribution / drug effects

  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. Sulfur, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604139.001).
  • [ISSN] 1567-2018
  • [Journal-full-title] Current drug delivery
  • [ISO-abbreviation] Curr Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Serum Albumin; 0 / rhenium sulfur colloid; 70FD1KFU70 / Sulfur; 7440-15-5 / Rhenium; YKH834O4BH / Epinephrine
  •  go-up   go-down


9. Kolganov AS: [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia]. Vopr Onkol; 2001;47(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia].
  • [Transliterated title] Eksperimental'naia khimioterapiia zlokachestvennykh opukholeĭ v sochetanii s kratkovremennoĭ obshcheĭ gipoksieĭ.
  • The effect of hypoxy on chemotherapy with emoxyl, 5-fluorouracil and bleomycin which are characterized by different affinities with oxygen has been investigated.
  • In an experiment using 96 rats, each weighing 180 g, subcutaneously inoculated with Walker's carcinosarcoma and carcinoma.
  • PC-1, combined use of chemotherapy and hypoxy was followed by a significant inhibition of tumor growth rate, against a background of significant drop in survival due to the increased toxic effect of the drugs.
  • Therefore, hypoxy cannot be recommended for modifying chemotherapy of tumors irrespective of drug affinity with oxygen.
  • [MeSH-major] Anoxia. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Carcinoma 256, Walker / therapy. Daunorubicin / analogs & derivatives. Daunorubicin / therapeutic use

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317544.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 84412-94-2 / Emoxyl; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


10. Nogusa H, Yamamoto K, Yano T, Kajiki M, Hamana H, Okuno S: Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents. Biol Pharm Bull; 2000 May;23(5):621-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma and tissue distribution of conjugates of carboxymethylpullulan (CMPul) and doxorubicin (DXR), either bound directly or through three types of tetrapeptide spacers, was studied after intravenous injection to rats bearing Walker 256 carcinosarcoma and compared with that of DXR.
  • Disposition characteristics of [3H]CMPul in rats bearing Walker 256 carcinosarcoma indicate that pullulan, which had molecular weight over 50 kDa, is a suitable macromolecular carrier for tumor targeting in cancer chemotherapy by carboxymethylation.
  • CMPul-DXR conjugates were also distributed in the reticuloendothelial organs, such as liver, spleen and bone marrow; however, the tissue concentrations of the conjugates in the heart, lung and muscle were lower than those of DXR.
  • We next investigated the effect of the DXR contents of CMPul-DXR conjugates on their body distribution in rats bearing Walker 256.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Carcinosarcoma / metabolism. Doxorubicin / pharmacokinetics. Glucans / pharmacokinetics
  • [MeSH-minor] Animals. Carbohydrate Sequence. Female. Male. Mice. Molecular Sequence Data. Peptides / administration & dosage. Peptides / chemistry. Rats. Rats, Wistar. Tissue Distribution. Tritium

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10823676.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucans; 0 / Peptides; 0 / carboxymethylpullulan; 10028-17-8 / Tritium; 80168379AG / Doxorubicin
  •  go-up   go-down


11. Zalietok SP, Orlovs'kyĭ OA, Hohol' SV, Samoĭlenko OA, Hulua L, Kvesitadze HI: [Effect of plant biocomposites based on Georgian tea "per se" and in combination with cisplatin on Walker carcinosarcoma W-256 and Guerin's carcinoma growth rate in rats]. Lik Sprava; 2006 Dec;(8):89-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of plant biocomposites based on Georgian tea "per se" and in combination with cisplatin on Walker carcinosarcoma W-256 and Guerin's carcinoma growth rate in rats].
  • Green tea biocomposite had effectivey hampered the growth of rat Walker W-256 carcinoma and in less extent rat Guerin's carcinoma.
  • Black tea biocomposite had not practically influenced on Guerin's carcinoma growth.
  • The biocomposite from green tea and extract from red vine rind and lemon suppressed at the level of tendency the growth of rat Walker W-256 carcinoma.
  • The biocomposite from green tea and extract from red vine rind had hampered only Guerin's carcinoma growth and at the tendency had increased the growth of W-256 carcinosarcoma growth.
  • This biocomposite increased also considerably the therapeutic efficiency of cisplatin on Guerin's carcinoma.

  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427433.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Kurth AA, Kim SZ, Shea M, Bauss F, Hayes WC, Müller R: Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis. J Bone Miner Metab; 2007;25(2):86-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.
  • Walker carcinosarcoma cells were implanted into the left femur of female rats that received 26-day ibandronate pretreatment followed by continued therapy or ibandronate posttreatment only.
  • At endpoint, excised femurs were scanned using microcomputed tomography (microCT) to assess bone volume density, bone mineral content, trabecular number/thickness, and separation for cortical plus trabecular bone or trabecular bone alone.
  • Compared with the nonimplanted right femur, bone volume and surface density and trabecular number and thickness were reduced in the distal left femur following tumor cell implantation. microCT analysis revealed greater cortical and trabecular bone mineral content in the preventative and interventional (pre-post tumor) ibandronate group, and the interventional (post-tumor) ibandronate group, versus the tumor-only group.
  • After preventative and interventional ibandronate, bone volume density and trabecular thickness were 13% and 60% greater, respectively, than in the post-tumor treatment group.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone and Bones / pathology. Carcinoma 256, Walker / pathology. Diphosphonates / therapeutic use
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Femur / drug effects. Femur / pathology. Image Processing, Computer-Assisted. Rats

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 May 15;99(10 ):2509-17 [9153295.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17 (7):1139-47 [12096826.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5452-7 [8221685.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 May;20(5):685-93 [6428894.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3890-4 [9307266.001]
  • [Cites] Phys Med Biol. 1994 Jan;39(1):145-64 [7651993.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] Br J Haematol. 1997 Sep;98(3):665-72 [9332325.001]
  • [Cites] Endocrinology. 1996 Jun;137(6):2324-33 [8641182.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] J Bone Miner Res. 1994 Feb;9(2):221-30 [8140935.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2027-34 [11697798.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):698-705 [8698861.001]
  • [Cites] Anat Rec. 1997 Dec;249(4):458-68 [9415453.001]
  • [Cites] Osteoporos Int. 2001;12 (11):936-41 [11804020.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):126-30 [10697328.001]
  • [Cites] Bone. 2004 Apr;34(4):736-46 [15050906.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3080-8 [10898355.001]
  • [Cites] Osteoporos Int. 2004 Jun;15(6):423-33 [15205712.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4418-24 [11389070.001]
  • [Cites] Bone. 2002 Jan;30(1):300-6 [11792601.001]
  • [Cites] J Bone Miner Res. 2003 Nov;18(11):1932-41 [14606504.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1478-87 [8686503.001]
  • [Cites] Osteoporos Int. 1998;8(2):97-103 [9666930.001]
  • [Cites] Calcif Tissue Int. 1996 Jan;58(1):24-9 [8825235.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):91-8 [8508433.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:453-65 [10415748.001]
  • [Cites] Mol Pharmacol. 1996 Nov;50(5):1127-38 [8913344.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10 ):1482-91 [8889848.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):468-77 [14506749.001]
  • [Cites] Osteoporos Int. 2002 Oct;13(10):816-23 [12378371.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1167-74 [10404017.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3551-7 [7627963.001]
  • [Cites] Cancer Res. 1984 Jul;44(7):3007-11 [6233002.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(6):539-43 [3119600.001]
  • [Cites] J Orthop Res. 2001 Mar;19(2):200-5 [11347691.001]
  • [Cites] J Cancer Res Clin Oncol. 1986;111(1):35-41 [3949849.001]
  • [Cites] Drugs. 2000 Mar;59(3):391-9 [10776826.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):94-8 [11310206.001]
  • [Cites] Oncology. 1988;45(1):41-6 [3340393.001]
  • [Cites] J Bone Miner Res. 2004 Nov;19(11):1787-96 [15476578.001]
  • (PMID = 17323177.001).
  • [ISSN] 0914-8779
  • [Journal-full-title] Journal of bone and mineral metabolism
  • [ISO-abbreviation] J. Bone Miner. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; UMD7G2653W / ibandronic acid
  •  go-up   go-down


13. Dubin M, Fernandez Villamil SH, Stoppani AO: [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]. Medicina (B Aires); 2001;61(3):343-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use].
  • [Transliterated title] Citotoxicidad de la beta-lapachona: una o-naftoquinona con posibles usos terapéuticos.
  • Initial observations proved its capability for inhibiting growth of Yoshida tumor and Walker 256 carcinosarcoma. beta-Lap redox-cycling in the presence of reductants and oxygen yields "reactive oxygen species" (ROS: O2-, OH and H2O2) which cytotoxicity led to assume its role in beta-lap activity in cells. beta-Lap inhibited DNA synthesis in Trypanosoma cruzi as well as topoisomerases I and II, poly(ADP-ribose) polymerase (PARP) in different cells.
  • These enzymes are essential for maintaining DNA structure. beta-Lap inhibited growth of a large variety of tumor cells including epidermoid laringeal cancer, prostate, colon, ovary and breast cancer and also different types of leukemia cells.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Naphthoquinones / pharmacology. Neoplasms / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Reactive Oxygen Species / physiology
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / enzymology. Humans. Sarcoma, Yoshida / drug therapy. Sarcoma, Yoshida / enzymology. Topoisomerase I Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474885.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Naphthoquinones; 0 / Reactive Oxygen Species; 0 / Topoisomerase I Inhibitors; 4707-32-8 / beta-lapachone; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 58
  •  go-up   go-down


14. Stepensky D, Golomb G, Hoffman A: Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci; 2002 Feb;91(2):508-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two rat models of bone disease were applied.
  • Bone cancer was produced by intratibial inoculation of Walker carcinosarcoma cells, and a model of augmented bone resorption was produced by vitamin D(3) treatment of rats that had undergone thyroidparathyroidectomy.
  • Higher amounts of alendronate were found in bones and in internal organs after bolus drug administration as compared with continuous infusion.
  • Drug effects on plasma calcium levels and on urine calcium excretion were similar in both modes of alendronate administration.
  • [MeSH-minor] Animals. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / urine. Bone Resorption / drug therapy. Calcium / blood. Calcium / urine. Carcinoma 256, Walker / blood. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / pathology. Carcinoma 256, Walker / urine. Drug Administration Schedule. Drug Evaluation, Preclinical / methods. Female. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / urine. Male. Neoplasm Transplantation. Parathyroidectomy. Rats. Rats, Sprague-Dawley. Rats, Wistar. Thyroidectomy. Tibia / pathology

  • Hazardous Substances Data Bank. Alendronic acid .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:508-516, 2002
  • (PMID = 11835209.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium; X1J18R4W8P / Alendronate
  •  go-up   go-down


15. Kurth AA, Kim SZ, Sedlmeyer I, Bauss F, Shea M: Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. Bone; 2002 Jan;30(1):300-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.
  • Bisphosphonate treatment is beneficial against symptoms of metastatic bone disease, although less is known about the effect of preventative treatment schedules.
  • We investigated the effect of various treatment regimens of the bisphosphonate, ibandronate (IB), on the preservation of bone quality in a rat model of tumor-induced osteolysis.
  • Osteolytic Walker 256 (W256) carcinosarcoma cells were implanted into the left femur of female Sprague-Dawley rats, resulting in a 10% reduction in bone mineral density (BMD), a 16% reduction in bone density (BD), and a 26% reduction in failure load compared with the right femur 28 days after implantation.
  • IB was administered subcutaneously in five different treatment schedules:.
  • (2) IB PRE-POST SHAM received the same IB administration, but with a sham operation;.
  • (4) IB PRE-0 received IB injections for 26 days and was then killed to serve as a time zero control; and (5) IB POST received sham injection with saline before W256 cell insertion, and then received IB injections for 28 days until killing.
  • We used dual-energy X-ray absorptiometry (DXA) to measure distal femur BMD and bone mineral content (BMC), peripheral quantitative computed tomography (pQCT) to measure distal femur BD, and torsion testing to obtain torsional failure load.
  • Combined preventative and interventional IB treatment best preserved bone mass and strength, although all treatment schedules resulted in significant improvement compared with untreated controls (TUMOR ONLY).
  • The possibility of reducing or even preventing skeletal morbidity in cancer patients with a high risk of developing metastatic spreading to bone is exciting, and warrants further exploration.
  • [MeSH-major] Bone Density / drug effects. Bone Neoplasms / drug therapy. Bone Neoplasms / physiopathology. Diphosphonates / therapeutic use. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / physiopathology
  • [MeSH-minor] Animals. Biomechanical Phenomena. Female. Fractures, Bone / prevention & control. Humans. Mammary Neoplasms, Experimental / complications. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / physiopathology. Osteolysis / drug therapy. Osteolysis / etiology. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11792601.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down






Advertisement